Clinical Trials Browser

Phase 2 × INDUSTRY × sabatolimab × Clear all

NCT04150029 2026-01-13

STIMULUS-AML1

Phase 2 Terminated

90 enrolled 26 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic